View Clinical Trial (Medical Research Study)

Comparison of the RevLite Electro-optic Q-Switched Neodymium-doped Yttrium Aluminium Garnet (EO QS Nd:YAG) Laser to a Fractionated Laser System - NCT00955461-10075(Clinical Trial 305178)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  New York
State:  
NY
Zip Code: 10075
Conditions: Photodamage - Irregular Pigmentation - Acne Scars
Purpose: The purpose of this study is to compare the results of treatment between the side of the face treated with the RevLite Laser and the side of the face treated with a fractionated laser system.
Study summary:
Criteria: Inclusion Criteria: - Fitzpatrick Skin Type I-VI and Wrinkle Class I - Between the ages of 25-65 - Evidence of bilateral dyschromia Exclusion Criteria: - Pregnant, lactating, or is planning to become pregnant - history of cutaneous photosensitization, porphyria, hypersensitivity to porphyrins or photodermatosis - any skin pathology/condition that could interfere with evaluation or requires the use of interfering topical or systemic therapy - coagulation disorder or currently using anti-coagulation medication (including but not limited to heavy aspirin therapy) - any condition which, in the investigator's opinion, would make it unsafe for the subject to participate in the study - currently enrolled in an investigational drug or device trial, or has received an investigational drug or been treated with an investigational device within 30 days - unable to communicate or cooperate with the investigator due to language problems, poor mental development, or impaired cerebral function - unreliable for the study, including subjects who engage in excessive alcohol intake or drug abuse, or subjects who are unable to return for scheduled follow-up visits - Accutane within 6 months - need to be exposed to artificial tanning devices or excessive sunlight during the trial - prior treatment with parenteral gold therapy - Diabetes Type 1 or 2 - does not agree to refrain from any other type of facial skin resurfacing (e.g., microdermabrasion, laser or IPL treatment, chemical peel) or injected fillers/other substances (e.g., Restylane, Botox) that might affect the treatment area for the duration of the study - artificial tanning within 1 month - (micro)dermabrasion within 3 months - other laser or IPL to the face within 6 months - chemical peel within 1 month - injectable fillers within 3 months - topical retinoids within 3 months - over-the-counter anti-aging products (e.g., those containing peptides, hyaluronic acid, or agents specifically advertised as having anti-aging or age-inhibiting properties) within 1 month - history of keloids or hypertrophic scarring - evidence of compromised wound healing - history of cold sores, chickenpox or shingles and unwilling to take a prophylactic course of Valtrex/acyclovir - allergy to acyclovir
Study is available at: Sadick Research Group
New York, NY 10075
United States

Primary Contact:
Elaine Kiang
Phone: 212-772-7242
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: March 23, 2011
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.